Compare · BBLG vs EW
BBLG vs EW
Side-by-side comparison of Bone Biologics Corp (BBLG) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $65.47B, about 3067.3x BBLG ($21.3M).
- Over the past year, BBLG is down 66.1% and EW is up 11.4% - EW leads by 77.5 points.
- EW has hit the wire 5 times in the past 4 weeks while BBLG has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- Edwards Lifesciences Corporation
- Price
- $1.40+0.72%
- $84.16+5.54%
- Market cap
- $21.3M
- $65.47B
- 1M return
- +21.74%
- +1.83%
- 1Y return
- -66.13%
- +11.37%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest BBLG
- Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Bone Biologics Corp
- SEC Form 10-K filed by Bone Biologics Corp
- SEC Form 4 filed by Chief Financial Officer Walsh Deina H
- SEC Form 4 filed by Chief Executive Officer Frelick Jeff
- Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
- SEC Form 10-Q filed by Bone Biologics Corp
- SEC Form S-8 filed by Bone Biologics Corp
Latest EW
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
- SEC Form DEFA14A filed by Edwards Lifesciences Corporation